Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare the efficacy of 2 different dose levels of AZD2281 versus liposomal doxorubicin in patients with advanced BRCA1 or BRCA2 associated ovarian cancer. This will be assessed by the following: primary variable · progression free survival (PFS) secondary variables · objective response rate (complete response (CR) and partial response (PR)) at various timepoints and overall · overall duration of response · tumour size · CA 125 levels · Overall survival (OS)
Critère d'inclusion
- Advanced BRCA1 or BRCA2 associated ovarian cancer whose disease has progressed or recurred after platinum based chemotherapy